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Objective: The aim of this study was to evaluate the effect of curcumin on body weight, glycemic control
and serum lipids in women suffering from polycystic ovary syndrome (PCOS).
Methods: The current randomized, double-blinded, placebo-controlled clinical trial was performed on 60
subjects with PCOS, aged 18e40 years old. Subjects were randomly allocated to take 500 mg/day cur-
cumin (n ¼ 30) or placebo (n ¼ 30) for 12 weeks. Glycemic control and serum lipids were measured at
baseline and after the 12-week intervention. Using RT-PCR method, gene expression related to insulin
and lipid metabolism was evaluated.
Results: Curcumin significantly decreased weight (0.8 ± 0.9 vs. 0.2 ± 0.8 kg, P ¼ 0.03) and BMI
(0.3 ± 0.4 vs. 0.1 ± 0.3 kg/m2, P ¼ 0.03). Curcumin, compared with the placebo, significantly reduced
fasting glucose (b 2.63 mg/dL; 95% CI, 4.21, 1.05; P ¼ 0.002), serum insulin (b 1.16 mIU/mL; 95%
CI, 2.12, 0.19; P ¼ 0.02), insulin resistance (b 0.26; 95% CI, 0.48, 0.03; P ¼ 0.02), and significantly
increased insulin sensitivity (b 0.006; 95% CI, 0.001, 0.01; P ¼ 0.02). In addition, taking curcumin was
associated with a significant reduction in total cholesterol (b 15.86 mg/dL; 95% CI, 24.48, 7.24;
P ¼ 0.001), LDL-cholesterol (b 16.09 mg/dL; 95% CI, 25.11, 7.06; P ¼ 0.001) and total-/HDL-choles-
terol ratio (b 0.62; 95% CI, 0.93, 0.30; P < 0.001), and a significant increase in HDL-cholesterol levels
(b 2.14 mg/dL; 95% CI, 0.36, 3.92; P ¼ 0.01) compared with the placebo. Additionally, curcumin
administration up-regulated gene expression of peroxisome proliferator-activated receptor gamma
(PPAR-g) (P ¼ 0.03) and low-density lipoprotein receptor (LDLR) (P < 0.001) compared with the placebo.
Conclusions: Overall, curcumin administration for 12 weeks to women with PCOS had beneficial effects
on body weight, glycemic control, serum lipids except triglycerides and VLDL-cholesterol levels, and gene
expression of PPAR-g and LDLR. Registered under Clinical Trials.gov Identifier no. http://www.irct.ir:
IRCT20170513033941N50.
© 2020 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights
reserved.1. Introduction
Polycystic ovary syndrome (PCOS) is one of the most prevalent
disorders worldwide with its global prevalence ranges from 4% to
21% [1]. This endocrine disorder affects various aspects of wom-
en's health and demonstrates with multiple clinical features andition and Metabolism. Published brelated comorbidities, including reproductive abnormalities,
prominent insulin resistance as well as increased risk of coronary
heart disease, type 2 diabetes mellitus (T2DM) and dyslipidemia
[2e5]. Patients suffering from PCOS represent with decreased
insulin sensitivity as well as b-cell dysfunction. Besides, dyslipi-
demia is one of the most common complications of PCOS
involving increased triglycerides and LDL-cholesterol as well as
decreased HDL-cholesterol levels [6]. Additionally, gene expres-
sion of low-density lipoprotein receptor (LDLR) has beeny Elsevier Ltd. All rights reserved.
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important role of gene expression of peroxisome proliferator-
activated receptor gamma (PPAR-g) in insulin signaling and
androgen production in PCOS [7]. Currently, life style in-
terventions including diet alterations are the first recommended
approach for these patients. In addition, complementary and
alternative medicine has become more popular in PCOS man-
agement, recently [8].
Curcumin is a polyphenolic compound derived from the famous
spice, turmeric. It is able to interact with awide variety ofmolecular
targets exerting many effects such as antioxidant, anti-
inflammatory, hypoglycemic and lipid-lowering activities [9,10].
Interestingly, curcumin administration has been shown to be
effective in improving various metabolic disorders such as obesity,
diabetes, metabolic syndrome, and cardiovascular disease by
improving body weight, insulin resistance, and lipid abnormalities
[11,12]. However, some studies have also reported contradictory
results [11,13,14]. A number of experimental and clinical studies
have revealed that curcumin is able to increase insulin sensitivity
by enhancing glucose homeostasis, b-cell function and insulin
secretion [15e18]. Furthermore, curcumin has been demonstrated
to be effective in controlling hyperlipidemic disorders by reducing
triglycerides, LDL-cholesterol and total cholesterol as well as
increasing HDL-cholesterol levels [19]. There are promising evi-
dence shows the importance of curcumin administration in pa-
tients with PCOS. To our knowledge, no investigation is currently
on-going to evaluate the effect of curcumin intake on metabolic
profiles in women with PCOS. Therefore, in this study, we aimed to
evaluate the effects of curcumin on body weight, glycemic control
and serum lipids in women with PCOS.Table 1





GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
PPAR-g F: ATGACAGACCTCAGACAGATTG 210 542. Subjects and methods
In a randomized, double-blind, placebo-controlled clinical trial,
sixty womenwere randomly enrolled to receive either 500 mg/day
curcumin or placebo (starch) (n ¼ 30 each group). Curcumin and
placebo were manufactured by Dineh (Tehran, Iran) and Barij
Essence (Kashan, Iran), respectively. Placebo and curcumin were
totally the same in color, shape, size, and packaging. Randomiza-
tion was made using computer-generated random numbers by a
trained staff at the gynecology clinic. During the study, we asked
patients to return medication containers to ensure that curcumin
supplements were used. Also, we remind patients to take the
supplements by cell phone. Study protocol was published in the
Iranian website for registration of clinical trials (www.irct.ir;no:
IRCT20170513033941N50). Eligible study participants were
womenwith PCOS diagnosed based on the Rotterdam criteria [20],
aged 18e40 years old whom referred to the outpatient Kosar Clinic
in Arak, Iran, and was conducted between January and May 2019.
The study protocol was approved by the Ethics Committee of Arak
University of Medical Sciences (AUMS). Written informed consent
was attained from all participants before the intervention. Exclu-
sion criteria were as follows: individuals with neoplastic disorders
cardiovascular diseases malabsorptive disorders current or previ-
ous (within the last 6 months), use of hormonal, antidiabetic and
anti-obesity medications prior to study inclusion.R: AATGTTGGCAGTGGCTCAG
GLUT-1 F: TATCTGAGCATCGTGGCCAT 238 62.1
R: AAGACGTAGGGACCACACAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
GAPDH, glyceraldehyde-3-Phosphate dehydrogenase; GLUT-1, glucose transporter
1; LDLR, low-density lipoprotein receptor; PPAR-g, peroxisome proliferator-
activated receptor gamma.2.1. Anthropometric measures
Anthropometric measurements were assessed by an expert
midwife at the clinic at baseline and the end of the intervention.
Height and weight (Seca, Hamburg, Germany) were measured withlight clothing without shoes. Body mass index (BMI) was calculated
as weight (kilograms) divided by height (meters) squared.
2.2. Assessment of outcomes
The homeostatic model assessment for insulin resistance
(HOMA-IR) and insulin levels were considered as the primary
outcomes. Other metabolic profiles, peroxisome proliferator-
activated receptor gamma (PPAR-g), low-density lipoprotein re-
ceptor (LDLR) and glucose transporter 1 (GLUT-1) expression were
recognized as the secondary outcomes.
2.3. Biochemical assessment
Fasting blood samples were collected from participants (15 mL)
at baseline and the end of the intervention. To ascertain fasting
plasma glucose (FPG) and serum lipids, enzymatic kits (Pars
Azmun, Tehran, Iran) with inter- and intra-assay coefficient vari-
ances (CVs) lower than 5% were used. Serum insulin values were
measured using an ELISA kit (Monobind, California, USA) with the
intra- and inter-assay CVs lower than 6%. HOMA-IR and the quan-
titative insulin sensitivity check index (QUICKI) were calculated
according to the suggested formulas [21].
2.4. RNA extraction and real-time PCR
Gene expression of PPAR-g, GLUT-1 and LDLR were determined
by quantitative RT-PCR, using the LightCycler technology (Roche
Diagnostics, Rotkreuz, Switzerland) with SYBR green detection and
Amplicon Kit (Table 1).
2.5. Sample size and statistical analyses
Type one (a) and type two errors (b) were defined as 0.05, and
0.20 (power ¼ 80%), respectively. According to our previously
published trial [22], we used 1.81 as the SD and 1.45 as the change
in mean (d) of HOMA-IR as a primary outcome parameter. Based on
the power analysis, we needed 25 subjects in each group; after
allowing for 5 dropouts in each group, the final sample size was 30
persons in each group.
The KolmogoroveSmirnov test was used to determine the
normality of variables. Independent-sample t-test was applied to
compare changes in anthropometric values, gene expression and
dietary intakes between the two groups. To evaluate the effect of
curcumin intake on metabolic status, we used multiple linear
regression. Significance of the treatment effects was presented as
Fig. 1. Summary of patient flow diagram.
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were considered statistically significant.
3. Results
As demonstrated in the study flow diagram (Fig. 1), during the
enrollment phase of the study, there were 65 women with PCOS;
however, 5 participants did not meet the inclusion criteria and thus
were excluded. During the follow-up, 6 participants in the curcu-
min group and 4 in the placebo group dropped out of the study due
to personal reasons. Finally, 50 participants [placebo (n ¼ 26) and
curcumin (n ¼ 24)] completed the trial.
Mean age, height, and baseline and end-of-trial weight and BMI
were not statistically different between the two groups (Table 2).
Curcumin significantly decreased weight (0.8 ± 0.9
vs.0.2 ± 0.8 kg, P¼ 0.03) and BMI (0.3 ± 0.4 vs.0.1 ± 0.3 kg/m2,
P ¼ 0.03).
There was no statistically significant difference in terms of di-
etary macro- and micronutrients intakes between curcumin and
placebo groups (Data not shown).
Curcumin, compared with the placebo, significantly reduced
FPG (b2.63mg/dL; 95% CI,4.21,1.05; P¼ 0.002), serum insulin
(b 1.16 mIU/mL; 95% CI, 2.12, 0.19; P ¼ 0.02), HOMA-IR
(b 0.26; 95% CI, 0.48, 0.03; P ¼ 0.02), and significantlyTable 2
General characteristics of study participants.a
Placebo
group (n ¼ 26)
Curcumin
group (n ¼ 24)
Pb
Age (y) 27.2 ± 3.4 28.6 ± 4.7 0.22
Height (cm) 164.2 ± 3.9 162.5 ± 4.4 0.15
Weight at study baseline (kg) 71.0 ± 9.5 72.1 ± 9.8 0.68
Weight at end-of-trial (kg) 70.8 ± 9.5 71.3 ± 9.8 0.83
Weight change (kg) 0.2 ± 0.8 0.8 ± 0.9 0.03
BMI at study baseline (kg/m2) 26.4 ± 3.8 27.4 ± 3.9 0.37
BMI at end-of-trial (kg/m2) 26.3 ± 3.8 27.1 ± 3.8 0.48
BMI change (kg/m2) 0.1 ± 0.3 0.3 ± 0.4 0.03
a Data are means± SDs.
b Obtained from independent t-test.increased QUICKI (b 0.006; 95% CI, 0.001, 0.01; P¼ 0.02) (Table 3). In
addition, taking curcumin was associated with a significant
reduction in total cholesterol (b 15.86 mg/dL; 95%
CI,24.48,7.24; P¼ 0.001), LDL-cholesterol (b16.09mg/dL; 95%
CI, 25.11, 7.06; P ¼ 0.001) and total-/HDL-cholesterol ratio
(b0.62; 95% CI,0.93,0.30; P< 0.001), and a significant increase
in HDL-cholesterol levels (b 2.14mg/dL; 95% CI, 0.36, 3.92; P¼ 0.01)
compared with the placebo.
Curcumin intake increased gene expression of PPAR-g (P ¼ 0.03)
andLDLR(P<0.001)comparedwith theplacebogroup (Figs. 2 and3).
Curcumin consumption did not affect gene expression of GLUT-
1 (P ¼ 0.12) compared with the placebo (Fig. 2).
4. Discussion
In this study, we evaluated for the first time the effects of the 12-
week intervention of curcumin intake on body weight, and meta-
bolic and genetic profiles related to insulin and lipid inwomenwith
PCOS. We found that curcumin administration for 12 weeks to
women with PCOS had beneficial effects on body weight, glycemic
control, serum lipids except triglycerides and VLDL-cholesterol
levels, and gene expression of PPAR-g and LDLR.
4.1. Effects on body weight and BMI
The prevalence of being overweight or obese is more among
PCOS women in comparison to healthy women [23]. Our results
indicated that curcumin consumption for 12 weeks significantly
reduced body weight and BMI in PCOS patients. Our findings were
in line with a clinical trial in which the role of curcumin on weight
loss was investigated [24]. However, in another clinical study,
curcumin intake did not improve body weight [25]. Obesity in-
creases the risk of metabolic complications and decreases quality of
life in PCOS patients. In addition, obese women with PCOS have
been observed to represent more severe morbidities such as higher
degrees of insulin resistance, hyperandrogenism and hyper-
insulinemia [26,27]. Curcumin may ameliorate body weight by
possible effects, including decreasing fat mass, endoplasmic
Table 3
Metabolic profiles at baseline and after the 12-week intervention in women with polycystic ovary syndrome that received either curcumin or placebo.a
Variables Placebo group (n ¼ 26) Curcumin group (n ¼ 24) Difference in outcome measures between curcumin and placebo groupsa
Baseline Week 12 Baseline Week 12 b (95% CI) Pb
FPG (mg/dL) 92.9 ± 4.2 92.5 ± 4.5 94.9 ± 6.1 91.2 ± 4.6 2.63 (4.21, 1.05) 0.002
Insulin (mIU/mL) 10.5 ± 2.5 10.6 ± 2.4 11.3 ± 3.6 10.1 ± 3.2 1.16 (2.12, 0.19) 0.02
HOMA-IR 2.4 ± 0.6 2.4 ± 0.5 2.7 ± 0.9 2.4 ± 0.8 0.26 (0.48, 0.03) 0.02
QUICKI 0.336 ± 0.011 0.335 ± 0.012 0.333 ± 0.018 0.338 ± 0.017 0.006 (0.001, 0.01) 0.02
Triglycerides (mg/dL) 155.6 ± 33.5 153.8 ± 33.3 163.6 ± 44.8 154.0 ± 29.4 5.58 (12.93, 1.77) 0.13
VLDL-cholesterol (mg/dL) 31.1 ± 6.7 30.8 ± 6.6 32.7 ± 8.9 30.8 ± 5.8 1.11 (-2.58, 0.35) 0.13
Total cholesterol (mg/dL) 179.5 ± 29.9 179.7 ± 28.1 192.0 ± 36.6 175.5 ± 39.7 15.86 (24.48, 7.24) 0.001
LDL-cholesterol (mg/dL) 104.9 ± 32.1 106.4 ± 29.4 119.6 ± 35.8 103.6 ± 38.5 16.09 (25.11, 7.06) 0.001
HDL-cholesterol (mg/dL) 43.5 ± 7.7 42.5 ± 8.0 39.6 ± 9.8 41.0 ± 9.6 2.14 (0.36, 3.92) 0.01
Total-/HDL-cholesterol ratio 4.2 ± 1.0 4.4 ± 1.0 5.1 ± 1.3 4.4 ± 1.3 0.62 (0.93, 0.30) <0.001
Data are mean ±SDs.
FPG, fasting plasma glucose; HOMA-IR, homeostasis model of assessment-insulin resistance; HDL-cholesterol, high density lipoprotein-cholesterol; LDL-cholesterol, low
density lipoprotein-cholesterol; QUICKI, quantitative insulin sensitivity check index; VLDL-cholesterol, very low density lipoprotein-cholesterol.
a “Outcome measures” refers to the change in values of measures of interest between baseline and week 12. b [difference in the mean outcomes measures between
treatment groups (curcumin group ¼ 1 and placebo group ¼ 0)].
b Obtained from multiple regression model (adjusted for baseline values of each biochemical variables).
Fig. 2. Effect of the 12-week intake with curcumin or placebo on expression ratio of
PPAR-g and GLUT-1 gene in PBMCs of PCOS women.
Fig. 3. Effect of the 12-week intake with curcumin or placebo on expression ratio of
LDLR gene in PBMCs of PCOS women. GLUT-1, glucose transporter 1; LDLR, low-density
lipoprotein receptor; PPAR-g, peroxisome proliferator-activated receptor gamma;
PCOS, polycystic ovary syndrome; PBMCs, peripheral blood mononuclear cells.
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energy expenditure [28].
4.2. Effects on glycemic control
In current study, we observed that curcumin intake for 12weeks
in PCOS subjects improved glycemic control. According to two
previous meta-analyses, curcumin could decrease fasting glucose,HbA1c and HOMA-IR [29,30]. However, two another meta-analyses
reported that curcumin consumption significantly decreased fast-
ing glucose and HbA1c, but did not affect HOMA-IR [31,32]. In
addition to mentioned effects, some randomized clinical trials re-
ported that curcumin intake in patients with T2DM and non-
alcoholic fatty liver disease significantly increased QUICKI [22,33].
Evidence revealed that long-termworsening of insulin resistance in
PCOS patients is a potent risk factor for developing of T2DM [34]. In
addition, insulin resistancemay be associatedwith decreased levels
of adiponectin and accumulation of ectopic fat in different tissues of
PCOS women. Curcumin improves these conditions via inducing
glucokinase activity in the liver, increasing peripheral glucose up-
take, and reducing insulin resistance. Furthermore, in our study
curcumin intake increased gene expression of PPAR-g, but did not
affect gene expression of GLUT1. In vitro and in vivo studies
demonstrated that curcumin exerts anti-diabetic effects by
increasing the gene expression of PPAR-g [35e37]. PPAR-g has
pleiotropic effects in improvement of glucose homeostasis, insulin
sensitivity and controlling gene expression which play key roles in
lipid and glucose metabolisms [38]. Curcumin may exert glucose-
lipid-lowering effects by increasing gene expression of PPAR-g
which leads to improvement of insulin secretion and lipid ho-
meostasis [39].4.3. Effects on serum lipids
We found that curcumin intake for 12 weeks in patients with
PCOS had positive effects on serum lipids except triglycerides and
VLDL-cholesterol levels. Lipid-lowering effects of curcumin have
been well investigated. In a meta-analysis conducted by Simental-
Mendía et al. [34], curcumin administration could significantly
decrease triglycerides and increase HDL-cholesterol, but did not
affect total cholesterol and LDL-cholesterol concentrations [40]. In
another meta-analysis, curcumin intake has indicated to reduce
total cholesterol, LDL-cholesterol and triglycerides, but did not
change HDL-cholesterol levels. In contrast, another meta-analysis
declared that curcumin administration had no significant effect
on triglycerides, total cholesterol, LDL-cholesterol and HDL-
cholesterol levels [32]. In addition, a significant reduction in total
cholesterol and triglycerides following the intake of curcumin
among patients with metabolic syndrome and related disorders
was seen, while HDL-cholesterol and LDL-cholesterol levels did not
change [30]. Dyslipidemia characterized by elevated triglycerides,
total cholesterol and LDL-cholesterol, and decreased levels of HDL-
M. Jamilian et al. / Clinical Nutrition ESPEN 36 (2020) 128e133132cholesterol, which is common in patients with PCOS especially
obese ones [41,42]. Curcumin ameliorates dyslipidemia and acti-
vates lipid metabolism through elevating lipoprotein lipase activity
to decrease triglycerides levels [43]. In addition, curcumin attenu-
ates free fatty acid of plasma, affects gastrointestinal absorption
and transportation of cholesterol, as well as limits the risk of lipid
peroxidation which induces inflammatory response [19]. Further-
more, the current study indicated that gene expression of LDLR
significantly increased after curcumin intervention. Multiple
experimental and animal studies have reported that curcumin is
able to induce gene expression of LDLR leading to ameliorate hy-
percholesterolemia [44e47]. Increased expression of LDLR leads to
increased catabolism of LDL-cholesterol and improvement of
cholesterol homeostasis. Thus, curcumin intake may reduce com-
plications related to dyslipidemia in PCOS patients via improving
lipid profiles and increasing expression of LDLR.
4.4. Limitation
Curcumin and placebo were provided two various companies.
This should be considered in the interpretation of our findings.
5. Conclusions
Overall, curcumin administration for 12 weeks to women with
PCOS had beneficial effects on body weight, glycemic control,
serum lipids except triglycerides and VLDL-cholesterol levels, and
gene expression of PPAR-g and LDLR.
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